Clinical Trial Update: Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of bevacizumab for adrenocortical carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Adrenocortical Carcinoma | Phase 2 | Status: WITHDRAWN